RxDoctor Payments Data

Esther Robbins, MD

Family Medicine · Seguin, TXNPI 1124475173

Payments from drug & device makers

$1,038in general payments, 2019–2025

Across 50 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$221
  • AbbVie$221
  • Novo Nordisk$148
  • GSK$112
  • Exact Sciences$77
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$59
  • plus $200 from 8 others

What the payments were for

  • Food & beverage$1,038100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,038 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$52,505
Medicare patients
143
Services billed
678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide63$88,729
OzempicSemaglutide49$54,095
FarxigaDapagliflozin Propanediol17$21,749
Estradiol36$2,307
Levothyroxine Sodium228$2,080
Bupropion XlBupropion Hcl49$1,924
Albuterol Sulfate HfaAlbuterol Sulfate54$1,463
Estradiol (Twice Weekly)Estradiol18$1,296
SynthroidLevothyroxine Sodium14$1,034
Hydroxychloroquine Sulfate16$899
Gabapentin86$895
Valsartan15$895
Losartan Potassium99$865
Metoprolol Succinate53$736
Rosuvastatin Calcium71$711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$221$88,72963 claims
Novo NordiskOzempic$148$54,09549 claims
AstraZenecaFarxiga$36$21,74917 claims
AbbVieSynthroid$221$1,03414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Seguin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →